Wednesday, 26 August 2026European Markets

FINANCIERE MARJOS Stock Over 24% Down In The Last 10 Sessions

Loading stream...

(vianews) - shares of financiere marjos (cac 40: finm.pa) dropped by a staggering 24.66% in 10 sessions from €0.15 to €0.11 at 05:59 est on monday, after five sequential sessions in a row of losses. cac 40 is rising 1.34% to €7,388.65, following the last session's upward trend.

about financiere marjos

financière marjos sa, together with its subsidiaries, engages in the creation, installation, acquisition, and operation of various companies in france and internationally. the company's portfolio includes manufacturing, sales, rental, and maintenance companies. the company was formerly known as clayeux sa and changed its name to financière marjos sa. the company is headquartered in paris, france.

earnings per share

as for profitability, financiere marjos has a trailing twelve months eps of €-3.71.

volume

today's last reported volume for financiere marjos is 134 which is 15.51% above its average volume of 58.

volatility

financiere marjos's last week, last month's, and last quarter's current intraday variation average was a negative 35.19%, a negative 0.63%, and a positive 16.41%.

financiere marjos's highest amplitude of average volatility was 35.19% (last week), 34.57% (last month), and 16.41% (last quarter).

more news about financiere marjos (finm.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com